AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230404006025/en/

Inquiries

Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005

Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

FAQ

When will AbCellera report its first quarter 2023 earnings?

AbCellera will report its first quarter 2023 earnings on May 4, 2023.

What time is the AbCellera earnings conference call?

The earnings conference call is scheduled for 2:00 p.m. PT on May 4, 2023.

Where can I access the AbCellera earnings call webcast?

The earnings call webcast can be accessed through AbCellera's Investor Relations website.

What does AbCellera do?

AbCellera specializes in antibody drug discovery, leveraging technology and data science to facilitate faster drug development.